All In Biotech

NDA 203188 · Vertex Pharms

Kalydeco

Ivacaftor · Oral · Cystic Fibrosis Transmembrane Conductance Regulator Potentiator

NovelBreakthrough therapyPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Jan 31, 2012

Approved uses

11

Original approval plus efficacy supplements

Registered trials

136

60 Phase 3, 11 recruiting

FAERS reports

7,984

5,947 serious, 327 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 23, 2026.

KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data [see Clinical Pharmacology (12.1) and Clinical Studies (14) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients aged 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data. ( 12.1 , 14 ) If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use. ( 1 )

Mechanism: Ivacaftor is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. Ivacaftor facilitates increased chloride transport by potentiating the channel open probability (or gating) of CFTR protein located at the cell surface. The overall level of ivacaftor-mediated CFTR chloride transport is dependent on the amount of CFTR protein at the cell surface and how responsive a particular mutant CFTR protein is to ivacaftor potentiation. CFTR Chloride Transport Assay in Fischer Rat Thyroid (FRT) cells expressing mutant CFTR...

Therapeutic areas: Respiratory

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 22, 2025 Supplement 41 · Efficacy · priority review OrphanLetterLabel
  • Dec 21, 2020 Supplement 34 · Efficacy · priority review OrphanLetterLabel
  • Sep 24, 2020 Supplement 33 · Efficacy · priority review OrphanLetterLabel
  • Apr 29, 2019 Supplement 29 · Efficacy · priority review OrphanLabelLetter
  • Aug 15, 2018 Supplement 28 · Efficacy · priority review OrphanLetterLabel
  • Jul 31, 2017 Supplement 26 · Efficacy · priority review OrphanLabelLetter
  • May 17, 2017 Supplement 19 · Efficacy · priority review OrphanLabelLetter
  • Feb 8, 2017 Supplement 22 · Efficacy OrphanLetterLabel
  • Dec 29, 2014 Supplement 14 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Feb 21, 2014 Supplement 4 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Jan 31, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLabelOther Important Information from FDA
1 products under this application
  • KALYDECO · IVACAFTOR 150MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ivacaftor" as an intervention, any sponsor and status, largest first.

All 136 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hospitalisation1,384
  • infective pulmonary exacerbation of cystic fibrosis611
  • pneumonia271
  • infection257
  • lower respiratory tract infection255
  • malaise255
  • death229
  • cough225
  • cystic fibrosis220
  • headache197
  • nasopharyngitis171
  • influenza162

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2012174
2013129
2014383
2015523
2016271
2017403
2018558
20191,037
2020896
2021593
2022651
2023598
2024750
2025695
2026323

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kalydeco (IVacaftor)

2024 spending

$28.7M

Beneficiaries

105

1,101 claims

Per beneficiary

$273,600

$465.28 per unit

View as table
YearSpending
2020$37,664,939
2021$25,900,494
2022$25,486,737
2023$25,099,036
2024$28,727,989

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 146 on PubMed

Sponsor: Vertex Pharmaceuticals

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.